Caris MPI, Inc., operating as Caris Life Sciences, is a TechBio company founded in 2008 that works at the intersection of molecular science and artificial intelligence. Its focus is precision oncology - developing molecular profiling and blood-based cancer diagnostics designed to characterise tumours at a genomic level and support more informed treatment decisions.
The company's technical work spans next-generation sequencing, whole genome sequencing, whole transcriptome sequencing, and AI-driven analytics. Its product portfolio includes MI Profile, which produces comprehensive molecular blueprints of a patient's cancer; MI Cancer Seek, a tool to guide precision oncology treatment decisions; and Caris ChromoSeq, which the company describes as the world's first combined Whole Genome Sequencing and Whole Transcriptome solution for cancer characterisation.
Caris Life Sciences positions itself at the convergence of healthcare, medical diagnostics, and computational biology. The company states it is backed by a team of scientific and medical professionals and describes its culture as driven by innovation, compassion, and purpose.
